In chronic myeloid leukemia, PTPRG hypermethylation drives resistance to tyrosine‐kinase inhibitors, underscoring its role in constraining aberrant growth signals (38). Here, PTPRG is linked to chronic myelogenous leukemia, BCR-ABL1 positive.